Bibliografa 2004 Jul-Aug;20(7-8):709-15
It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
In clinical trials, about 74% of people on the 25-milligram oral dose experienced some gastrointestinal symptomsprimarily nausea, vomiting, or diarrhea
Reducing dosage and keep dosing frequency would make more sense due to the pk rationale I agree, particularly after several years, once habits regarding exercise, portion control and simply becoming more accustomed to some degree of hunger as being acceptable, I have found this effective
The FDA labeling includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though the relevance to humans remains uncertain
These benefits make them a versatile treatment option for patients looking to improve both appearance and long-term health outcomes
